Pfizer COVID-19 vaccine 94% effective in real-world conditions: study
Fox News
A coronavirus vaccine developed by Pfizer and BioNTech showed to drop symptomatic COVID-19 by 94%, per new research out of Israel. The peer-reviewed results offer a first look at effectiveness in real-world conditions, and showed consistency with high 95% vaccine efficacy reported during clinical trials.
A peer-reviewed study of a nationwide immunization effort is important to assess vaccine effectiveness in real-world, noncontrolled conditions compared to clinical trials, and account for difficulties maintaining the cold chain, vaccination schedule, and rolling the vaccine out among many more people of diverse populations, including those with chronic diseases, researchers wrote. Individuals aged under 16 were excluded, though Pfizer is currently running clinical trials in this age group. A week after two doses were administered, the team documented 87% effectiveness in dropping hospitalizations, a 92% cut in severe disease and 92% effectiveness for documented infection, compared to 14-20 days after an initial dose at 74%, 62% and 46%, respectively.More Related News